SOURCE-LINKED STUDY SUMMARY
Incretin hormones: Their role in health and disease.
Abstract summarized · Quality not appraised
- Studied
- An abstract-based overview explained how the gut peptides GIP and GLP-1 contribute to the incretin response and relate to type 2 diabetes, obesity and incretin-based medicines.
- Who / model
- It discusses healthy people and people with type 2 diabetes; no participant count or timeframe is reported.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- Found
- Oral glucose produced two to three times the insulin response of intravenous glucose. In type 2 diabetes, GIP effectiveness was reduced, while pharmacological GLP-1 receptor stimulation reduced plasma glucose and improved glycaemic control.
- Limits
- No author-stated limitation was available in the abstract. This broad overview does not report a single study sample, assigned comparator or follow-up period.
Read summary source ↗ · Prepared 9/22/2026 · AI-assisted, source-based summary
Research findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1111/dom.13129